Effect of Psiguavin for Obesity Treatment (PSIGUAVIN)

Summary

The main objective of the project focuses on the study of the effectiveness of a functional component extracted from Psidium guava, psiguavin, as a potential inhibitor of pancreatic lipase and, therefore, as an adjuvant for the treatment of obesity. That is, the aim is to verify from various experimental perspectives the effect of psiguavin on the activity of the enzyme pancreatic lipase (EC 3.1.1.3), which is the main enzyme responsible for the digestion of lipids from the diet. Our preliminary studies have shown that there is a strong interaction between psiguavin and the active center of pancreatic lipase; however, it is necessary to confirm these initial hypotheses through a clinical trial. Taking into account that the usefulness of this compound is based on the reduction of dietary calorie intake, in order to confirm its therapeutic usefulness, a clinical trial will be proposed. To this end, the following specific objective is defined, which is intended to be achieved with the execution of the project: • Evaluate the effect of psiguavin on weight loss of people with overweight/obese people.

Timeline

Start

2025-01-08

Primary completion

2026-12-19

Completion

2027-12-19

Drugs

Indications